Zhang Ting, Ji Guangquan, Feng Tianpu, Lin Xi, Wang Lei, Xu Yi, Shi Pan, Liang Wenxue
Department of Clinical Laboratory, The Affiliated Lianyungang Hospital of Xuzhou Medical University (The First People's Hospital of Lianyungang), Lianyungang, Jiangsu, China.
School of Pharmacy, Jinzhou Medical University, Jinzhou, Liaoning, China.
Appl Bionics Biomech. 2025 May 11;2025:6687606. doi: 10.1155/abb/6687606. eCollection 2025.
Diabetic retinopathy (DR) and diabetic cataract (DC) are two closely related microvascular complications of diabetes. , a plant from the Araliaceae family and genus Panax, is widely used in traditional Chinese medicine (TCM) due to its antioxidant, anti-inflammatory, and blood circulation-promoting properties. Recent studies suggest that drugs possessing anti-inflammatory, antioxidant, and blood circulation-promoting characteristics may have unexpected benefits in treating diabetic microvascular complications. This study employs network pharmacology to investigate the mechanisms by which can treat DR and DC as comorbidities. The study aims to explore the active components and biological mechanisms of in treating these comorbidities using network pharmacology and molecular docking. Components of were identified through literature reviews and database queries. Active components were selected based on drug-like principles, and their targets were predicted using the principle of similarity. Disease-related genes were collected from OMIM and GeneCards and scored. Venn analysis identified target nodes, followed by protein-protein interaction (PPI) network analysis, gene ontology (GO) analysis, and KEGG pathway analysis. Topological algorithms analyzed the PPI network, and key nodes combined with other analysis results were utilized to construct a -active component-gene-phenotype network using Cytoscape 3.9.1. Molecular docking on key genes, integrated with biological background, determined potential therapeutic targets against the diseases. contains eight active components and 234 potential gene targets. Network analysis showed that can repair microvascular damage by influencing disease-related signaling pathways. Molecular docking indicated that four key targets (SRC, JAK2, IGF1R, and EGFR) effectively bind to the active components of . These findings provide insights into the molecular-level action of against these diseases. Overall, this study enhances our understanding of the potential of in treating DR and DC as comorbidities and establishes a foundation for further research.
糖尿病视网膜病变（DR）和糖尿病性白内障（DC）是糖尿病两种密切相关的微血管并发症。人参是五加科人参属植物，因其具有抗氧化、抗炎和促进血液循环的特性，在传统中医（TCM）中被广泛应用。最近的研究表明，具有抗炎、抗氧化和促进血液循环特性的药物在治疗糖尿病微血管并发症方面可能有意外的益处。本研究采用网络药理学方法研究人参治疗DR和DC合并症的机制。该研究旨在利用网络药理学和分子对接技术探索人参治疗这些合并症的活性成分和生物学机制。通过文献综述和数据库查询确定人参的成分。根据类药原则选择活性成分，并利用相似性原则预测其靶点。从OMIM和GeneCards收集疾病相关基因并进行评分。通过韦恩分析确定靶点节点，随后进行蛋白质-蛋白质相互作用（PPI）网络分析、基因本体（GO）分析和KEGG通路分析。拓扑算法分析PPI网络，并利用关键节点结合其他分析结果，使用Cytoscape 3.9.1构建人参-活性成分-基因-表型网络。对关键基因进行分子对接，并结合生物学背景确定针对这些疾病的潜在治疗靶点。人参含有八种活性成分和234个潜在基因靶点。网络分析表明，人参可通过影响疾病相关信号通路修复微血管损伤。分子对接表明，四个关键靶点（SRC、JAK2、IGF1R和EGFR）与人参的活性成分有效结合。这些发现为人参针对这些疾病的分子水平作用提供了见解。总体而言，本研究加深了我们对人参治疗DR和DC合并症潜力的理解，并为进一步研究奠定了基础。
